Advertisement

Table of Contents

Masters of Immunology

  • Masters of Immunology
    Innate Lymphoid Cells in Cancer
    Blandine Vallentin, Vincent Barlogis, Christelle Piperoglou, Sophie Cypowyj, Nicolas Zucchini, Matthieu Chéné, Florent Navarro, Catherine Farnarier, Eric Vivier and Frédéric Vély
    Cancer Immunol Res October 1 2015 3 (10) 1109-1114; DOI:10.1158/2326-6066.CIR-15-0222

Cancer Immunology at the Crossroads: Experimental Immunotherapies

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures | AuthorChoice
    Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
    Sarah Derks, Katie S. Nason, Xiaoyun Liao, Matthew D. Stachler, Kevin X. Liu, Jie Bin Liu, Ewa Sicinska, Michael S. Goldberg, Gordon J. Freeman, Scott J. Rodig, Jon M. Davison and Adam J. Bass
    Cancer Immunol Res October 1 2015 3 (10) 1123-1129; DOI:10.1158/2326-6066.CIR-15-0046

    Esophageal adenocarcinoma and Barrett's esophagus epithelial cells commonly express PD-L2 in the setting of a Th2-skewed chronic inflammatory environment. Additional tumors express PD-L1 in immune cells. Evaluation of PD-1 inhibition and PD-L2 as biomarkers is warranted.

Priority Brief

  • Priority Brief
    Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer
    Katarzyna Urbanska, Caitlin Stashwick, Mathilde Poussin and Daniel J. Powell Jr
    Cancer Immunol Res October 1 2015 3 (10) 1130-1137; DOI:10.1158/2326-6066.CIR-15-0047

    Ovarian cancers, and possibly tumor-associated vasculature, express follicle-stimulating hormone receptors (FSHRs), a potential target for antitumor immunity. T cells expressing anti-FSHR receptors killed tumors expressing the FSHR in vitro and reduced tumor growth in mouse models.

Research Articles

  • Research Articles
    Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus–Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma
    Yong Zheng, Greg Parsonage, Xiaodong Zhuang, Lee R. Machado, Christine H. James, Asmaa Salman, Peter F. Searle, Edwin P. Hui, Anthony T.C. Chan and Steven P. Lee
    Cancer Immunol Res October 1 2015 3 (10) 1138-1147; DOI:10.1158/2326-6066.CIR-14-0203-T

    Nasopharyngeal carcinomas contain Epstein-Barr virus, with potentially immunogenic target epitopes. An HLA A*1101–restricted T-cell receptor (TCR) with specificity for LMP2 was cloned, could activate both CD4+ and CD8+ T cells, and inhibited tumor growth in a mouse model.

  • Research Articles
    Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
    Benjamin Boyerinas, Caroline Jochems, Massimo Fantini, Christopher R. Heery, James L. Gulley, Kwong Yok Tsang and Jeffrey Schlom
    Cancer Immunol Res October 1 2015 3 (10) 1148-1157; DOI:10.1158/2326-6066.CIR-15-0059

    Inhibition of PD-L1 interferes with an immunosuppressive signal, thereby prolonging antitumor responses. A novel monoclonal antibody to PD-L1 also mediated antibody-dependent cell-mediated cytotoxicity (ADCC) of tumor cells, an additional mode of action for checkpoint inhibitors.

  • Research Articles
    Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
    Marcella Callea, Laurence Albiges, Mamta Gupta, Su-Chun Cheng, Elizabeth M. Genega, André P. Fay, Jiaxi Song, Ingrid Carvo, Rupal S. Bhatt, Michael B. Atkins, F. Stephen Hodi, Toni K. Choueiri, David F. McDermott, Gordon J. Freeman and Sabina Signoretti
    Cancer Immunol Res October 1 2015 3 (10) 1158-1164; DOI:10.1158/2326-6066.CIR-15-0043

    Response to PD-L1 inhibition depends on its expression. Primary ccRCC tumors and their matching metastases were compared, and because PD-L1 was mostly in high nuclear-grade areas, these should be specifically selected for assessment to limit false negatives.

  • Research Articles | AuthorChoice
    Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
    Andrea M. Griesinger, Rebecca J. Josephson, Andrew M. Donson, Jean M. Mulcahy Levy, Vladimir Amani, Diane K. Birks, Lindsey M. Hoffman, Steffanie L. Furtek, Phillip Reigan, Michael H. Handler, Rajeev Vibhakar and Nicholas K. Foreman
    Cancer Immunol Res October 1 2015 3 (10) 1165-1174; DOI:10.1158/2326-6066.CIR-15-0061

    Subgroup A ependymoma are brain tumors with a poor prognosis. Tumors were found to be IL6/STAT3-dependent and infiltrated with polarized myeloid cells. Targeting this pathway to relieve immunosuppression could be an important approach for this tumor type.

  • Research Articles
    A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells
    Shu-Han Yu, Qizhi Zheng, David Esopi, Anne Macgregor-Das, Jun Luo, Emmanuel S. Antonarakis, Charles G. Drake, Robert Vessella, Colm Morrissey, Angelo M. De Marzo and Karen S. Sfanos
    Cancer Immunol Res October 1 2015 3 (10) 1175-1184; DOI:10.1158/2326-6066.CIR-15-0013

    The source of the IL6 production in prostate cancer was found to be tumor vasculature, not primary or metastatic tumor cells. This paracrine source may explain the low clinical activity of monoclonal antibodies targeting IL6 in prostate cancer.

  • Research Articles
    Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
    Sree Harsha Tirumani, Nikhil H. Ramaiya, Abhishek Keraliya, Nancy D. Bailey, Patrick A. Ott, F. Stephen Hodi and Mizuki Nishino
    Cancer Immunol Res October 1 2015 3 (10) 1185-1192; DOI:10.1158/2326-6066.CIR-15-0102

    As more melanoma patients are treated with CTLA-4 antibodies, immune-related adverse effects (irAEs) need elucidation. Radiographic imaging identified irAEs in 31% of patients, with colitis being most common. Most irAEs developed within 3 months of therapy.

Back to top
Cancer Immunology Research: 3 (10)
October 2015
Volume 3, Issue 10

Sign up for alerts

Jump to

Advertisement